Deutsche Bank Aktiengesellschaft Initiates Coverage on Sarepta Therapeutics (NASDAQ:SRPT)

Equities research analysts at Deutsche Bank Aktiengesellschaft assumed coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) in a research report issued on Tuesday, MarketBeat reports. The firm set a “hold” rating and a $136.00 price target on the biotechnology company’s stock. Deutsche Bank Aktiengesellschaft’s price objective points to a potential upside of […]